31 March 2023
Oncode Clinical Proof of Concept funded International Leukemia Target Board (iLTB) is now ready for its next steps
Oncode Investigator Monique den Boer, in collaboration with Judith Boer, Uri Ilan and the team of the trial and data center (headed by Michel Zwaan of the Princess Máxima Center) initiated the International Leukemia Target Board (iLTB). From its start, the initiative was funded through Oncode’s Clinical Proof of Concept (CPoC) programme. The base-laying set-up of the project is now finalized, and with the additional funding it has received, it is ready to continue into its execution phase.
17 March 2023
New study Sjoerd van der Burg Lab on underlying mechanisms in immunotherapy resistance
A new study from the lab of Oncode Investigator Sjoerd van der Burg (LUMC) was published in the Journal for ImmunoTherapy of Cancer (JITC) this week. The study focuses on understanding why some cancer treatments that use the body's immune system (immunotherapy) don't work as well as they should.
16 March 2023
Cyclomics starts new research collaboration with Oxford Nanopore Technologies
Research collaboration has resulted in new ‘liquid biopsy’ research workflow using nanopore sequencing to detect molecules that are associated with cancer, circulating in blood. Cyclomics is an UMC Utrecht spinoff company, co-founded by Oncode Investigator Jeroen de Ridder. Cyclomics obtained initial funding via the Oncode Bridge Fund.
7 March 2023
Hugo Snippert wins 2023 Ammodo Science Award for fundamental research
Oncode Investigator Hugo Snippert (UMCU) won the prestigious Ammodo Science Award for fundamental research 2023. He is one of the eight selected scientists selected from across four scientific domains, receiving a cash prize of 350.000 euros, which he can use in the coming years to explore new avenues of fundamental scientific research.
3 March 2023
Oncode Investigators Tineke Lenstra and Jurgen Marteijn receive ENW-M collaborative grant
Oncode Investigators Tineke Lenstra (NKI) and Jurgen Marteijn (Erasmus MC) have been awarded an ENW-M collaborative grant by the Dutch Research Council (NWO). The ENW-M grants are intended for curiosity driven scientific research with impact. In this collaboration, they aim to understand what happens with Pol II and transcription when Pol II stalls at DNA damage sites.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more